Gilead appoints Ted Love, MD, to Board of Directors; board expands to 10

GILEAD SCIENCES, INC.

Dr. Love elected to Board effective February 1, 2024; board size increased from 9 to 10.
He will serve on Audit Committee beginning after 2024 Annual Meeting, subject to reelection.
Dr. Love is former CEO of Global Blood Therapeutics and current chair of BIO board.
He also serves on boards of Royalty Pharma and Structure Therapeutics.
No arrangement or related-party transactions exist in connection with his appointment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ted W. Love, M.D.

Director

GILD · GILEAD SCIENCES, INC.

Effective: 2024-02-01
Filed: February 2, 2024, 6:59 PM ET

the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to serve on the Board, effective immediately after the close of such meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ted W. Love, M.D. was elected as Director at GILEAD SCIENCES, INC..

Action: elected
Role: Director

Exact text from the filing

the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to serve on the Board, effective immediately after the close of such meeting.

View on SEC.gov

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-010051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.